Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share transaction price of 1,481.088 pence per Ordinary Share.
Material Changes
The filing details an increase in shareholdings for specific individuals following the re-investment of dividends paid on July 5, 2012. There is no information regarding material changes in the company's operational or financial performance compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports on compliance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c) regarding insider transactions.
Key Facts for Investor Verification
- Transaction Type: Increase in share interests via dividend re-investment.
- Transaction Date: July 5, 2012 (dividend payment) and July 6, 2012 (notification).
- Share Price: 1,481.088 pence per Ordinary Share.
- Directors/PDMRs Involved: Sir Andrew Witty (643 shares), Dr D Pulman (333 shares), and Mrs V A Whyte (no shares acquired).
- Connected Persons Involved: Lady C Witty (1,588 shares), Mrs C R Pulman (68 shares), and Mr I W Whyte (96 shares).